Small Lymphocytic Lymphoma- Pipeline Insight, 2024

Small Lymphocytic Lymphoma- Pipeline Insight, 2024

DelveInsight’s, “Small Lymphocytic Lymphoma- Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Small Lymphocytic Lymphoma: Understanding

Small Lymphocytic Lymphoma: Overview

SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood. SLL that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body). Due to lower red blood cells (anaemia) and low platelet numbers in the bloodstream (thrombocytopenia) fatigue, shortness of breath and a tendency to bruise or bleed may occur. These symptoms may require transfusions of red blood cells or platelets. This problem is referred to as bone marrow failure and is due to the normal bone marrow being over-run by cancerous B cells. SLL can inhibit the immune system and make fighting infections more difficult. It can also cause the immune system to attack itself which is known as autoimmunity. When this occurs, two life-threatening conditions may develop. When the immune system attacks red blood cells, a process referred to as auto-immune haemolytic anaemia (AIHA) occurs. Approximately 7% of patients with SLL have AIHA at some stage. SLL affects adults and is usually diagnosed in people aged over 60 years. The median age of people at diagnosis is 65 years and is more common in men than in women. The causes of SLL are unknown. Doctors and researchers continually work to understand the exact mechanisms that cause this disease. It is not infectious and cannot be passed on to other people. Genetic testing for SLL is recommended prior to the treatment starting. This identifies any chromosomal abnormalities or specific gene mutations prior to treatment and is important to help treatment team decide on the most appropriate treatment. Treatment for SLL may involve the use of low or high intensity combination chemotherapy, more recently with a targeted therapy such as a monoclonal antibody. This is commonly known as chemo immunotherapy. The combination of drugs will depend on age, stage of disease and risk factors.

“Small Lymphocytic Lymphoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Lymphocytic Lymphoma pipeline landscape is provided which includes the disease overview and Small Lymphocytic Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Small Lymphocytic Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Lymphocytic Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Small Lymphocytic Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Small Lymphocytic Lymphoma.

Small Lymphocytic Lymphoma Emerging Drugs Chapters

This segment of the Small Lymphocytic Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Small Lymphocytic Lymphoma Emerging Drugs

• TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

• LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. Pirtobrutinib is currently being studied in multiple clinical trials. Safety and efficacy have not been established for the uses being studied.

• IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

Further product details are provided in the report……..

Small Lymphocytic Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Small Lymphocytic Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Small Lymphocytic Lymphoma

There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

• Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Small Lymphocytic Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Small Lymphocytic Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Lymphocytic Lymphoma drugs.

Small Lymphocytic Lymphoma Report Insights

• Small Lymphocytic Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Small Lymphocytic Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Small Lymphocytic Lymphoma drugs?
• How many Small Lymphocytic Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Lymphocytic Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Lymphocytic Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Small Lymphocytic Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Loxo Oncology
• Chia Tai Tianqing Pharmaceutical Group
• Iovance Biotherapeutics
• Ascentage Pharma
• NovalGen
• Pfizer
• MingSight Pharmaceuticals
• Jiangsu MingSight-Relin Pharmaceutical
• TG Therapeutics

Key Products

• TQ-B3525
• LOXO-305
• IOV 2001
• Venetoclax
• APG2575
• NVG-111
• MS-553
• Ublituximab
• JCAR017